Related Experiment Videos
Summary
Verapamil effectively terminates supraventricular tachycardia and manages atrial fibrillation and flutter. This calcium channel blocker is a primary treatment for various tachyarrhythmias, offering significant clinical benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Verapamil's antiarrhythmic properties were recognized prior to its identification as a calcium ion-antagonist.
- Calcium channel blockers play a crucial role in managing cardiac arrhythmias.
Purpose of the Study:
- To review the antiarrhythmic effects of verapamil.
- To highlight verapamil's efficacy in different supraventricular and ventricular tachyarrhythmias.
Main Methods:
- Clinical observations and established data on verapamil's use in treating tachyarrhythmias.
- Review of pharmacological actions and clinical outcomes.
Main Results:
- Intravenous verapamil effectively terminates paroxysmal reciprocating atrioventricular tachycardia.
- Verapamil consistently slows ventricular response in atrial fibrillation and increases AV-nodal block in atrial flutter.
- Oral verapamil is beneficial for prophylaxis of atrioventricular reentry tachycardia and modulating atrial fibrillation.
Conclusions:
- Verapamil is the preferred agent for terminating paroxysmal supraventricular tachycardia.
- It demonstrates significant utility in managing atrial fibrillation and flutter, with specific applications in ventricular tachycardia.
- Verapamil's role as a calcium ion-antagonist underpins its broad antiarrhythmic actions.